WeVote
Log In

Bill

Bill

SB 303

Pharmacy Benefits Managers - Definition of Purchaser and Alteration of Application of Law

2025 Regular Session Introduced by Clarence Lam

Maryland bill redefines PBM "purchaser" status and alters regulatory application, potentially shifting which pharmacy benefit manager practices face oversight and compliance requirements.

Hearing 2/05 at 2:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · SB 303

Legislative bill overview

SB 303 modifies Maryland law regarding Pharmacy Benefits Managers (PBMs) by redefining what constitutes a "purchaser" and altering how existing PBM regulations apply. The bill appears to create new legal categories or exemptions that change which entities fall under PBM oversight and how current regulations are enforced.

Why is this important

PBMs control medication pricing, formularies, and access for millions of Marylanders through insurance plans. Changes to how they're regulated directly affect drug costs, medication availability, and insurance premiums for consumers and employers. This definitional shift could expand or narrow regulatory requirements, influencing transparency and competitive practices in the pharmaceutical supply chain.

Potential points of contention

  • Scope of exemptions: The redefinition of "purchaser" may exempt certain PBM activities from regulation, potentially reducing consumer protections or accountability for pricing practices
  • Competitive impact: Changes could advantage larger PBMs or specific corporate structures while disadvantaging smaller competitors or independent pharmacies
  • Insurance costs: Altering PBM oversight could either increase transparency and lower drug costs, or reduce compliance burdens and potentially raise prices, depending on implementation

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.